<DOC>
	<DOCNO>NCT01880216</DOCNO>
	<brief_summary>Deep-vein thrombosis ( DVT ) common under-diagnosed medical condition occur thrombus form one large vein , usually low limb , lead either partial complete block circulation . The condition may progress severe health complication , pulmonary embolism ( PE ) , diagnose treat timely effective manner . The goal therapy lower-extremity DVT prevent extension thrombus pulmonary embolism short term prevent recurrent event long-term . Although anticoagulant therapy decrease risk recurrent thrombosis , treatment also increase risk major hemorrhage . This trial aim optimize current medical knowledge effectiveness safety two low molecular weight heparin , bemiparin enoxaparin treatment deep vein thrombosis .</brief_summary>
	<brief_title>Efficacy Bemiparin Versus Enoxaparin Treatment DVT</brief_title>
	<detailed_description>The aim study demonstrate therapeutic non-inferiority bemiparin sodium ( LMWH ) versus enoxaparin sodium ( LMWH ) 7±2 day treatment period follow 11 week observation period . Primary endpoint : The percentage patient improvement thrombotic burden Visit 3 ( Day 83 ) define ≥4-point reduction thrombus score ( least halve thrombus score , total score ≤ 6 ) , without confirm symptomatic extension recurrence DVT , confirm symptomatic PE , VTE-related death Visit 3 ( Day 83 / Month 3 ) , measure complete compression ultrasound ( cCUS ) Duplex sonography accord standardize protocol . Secondary endpoint : The secondary efficacy endpoint define : • Incidence symptomatic venous thromboembolic event ( VTE ) Visit 3 ( Day 83 : - Recurrent DVT - Pulmonary embolism Incusion criterion : Patients acute deep-vein thrombosis leg ( DVT ) symptoms less 14 day , confirm complete compression ultrasound ( cCUS ) within 48 hour prior study start . Patients give sign declaration consent data protection declaration Males females age 18 year</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Enoxaparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>1 . Patients acute deepvein thrombosis leg ( DVT ) symptoms less 14 day confirm complete compression ultrasound ( cCUS ) within 48 h prior study start . 2 . Males female age ≥18 year 3 . Patients give write informed consent . Specific 1 . History presence familial bleeding diathesis , presence active bleeding contraindicate anticoagulant therapy , well presence clinically relevant coagulation clot factor disorder , thrombocytopenia 2 . Patients undergone thrombectomy , insertion caval filter treat fibrinolytic agent treat current episode DVT 3 . Treatment heparin ( fractionate unfractionated ) , fondaparinux vitamin K antagonist warfarin treatment DVT 48 h prior enrolment 4 . Longterm treatment vitamin K antagonist , i.e . atrial fibrillation , myocardial infarction cardiomyopathy 5 . Isolated distal calf vein thrombosis 6 . Isolated superficial vein thrombosis 7 . Any symptomatic venous thromboembolism beside DVT 8 . Known hypersensitivity heparin ( include pigderived substance ) , study medication heparinderivatives include LMWHs , warfarin and/or active ingredient excipient study medication 9 . Concurrent treatment platelet function inhibitor ( acetylsalicylic acid , ticlopidine , clopidogrel , NSAID ) , fibrinolytic agent anticoagulant agent , Glycoprotein IIb/IIIa receptor antagonist , nitroglycerine iv , systemic glucocorticoid , penicillin high dos , dextran , ascorbic acid , digitalis , tetracycline , medical product could increase potassium plasma level 10 . History document suspect heparininduced thrombocytopenia ( HIT I II ) platelet count le 100,000 platelet per mm3 11 . Ischaemic stroke one month prior enrolment 12 . History active intracranial disorder ( cerebral vascular aneurysm , arteriovenous malformation cerebral neoplasm ) , history haemorrhagic stroke intracranial bleed 6 month prior enrolment , active haemorrhage increase risk bleeding due impaired haemostatics organ lesion ( e.g . peptic ulcer , hepatic failure , haemorrhagic stroke , macroscopic visible urogenital bleeding , cerebral vascular aneurysm cerebral neoplasm ) 1 month prior enrolment . 13 . Uncontrolled arterial hypertension : systolic blood pressure &gt; 200 mmHg diastolic blood pressure &gt; 105 mmHg . 14 . Severe impairment pancreas function , history gastroduodenal ulcer disease , nephrolithiasis and/or ureterolithiasis , choroid retinal vascular disease , suspect vascular retinopathy , vitreous haemorrhage intraocular bleeding , organic lesion increase risk bleeding . 15 . Significant liver disease ( e.g . acute hepatitis , chronic active hepatitis , hepatic cirrhosis , hepatic encephalopathy ) liver enzyme ( ALT and/or AST ) &gt; 5x ULN . others</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Deep vein thrombosis</keyword>
	<keyword>DVT</keyword>
	<keyword>Treatment</keyword>
	<keyword>Low molecular weight heparin</keyword>
	<keyword>Bemiparin</keyword>
	<keyword>Enoxaparin</keyword>
</DOC>